Overview of the marmoset as a model in nonclinical development of pharmaceutical products

Regulatory Toxicology and Pharmacology

Volumn 59, Issue 1, 2011, Pages 19-27

  Orsi, Antonia ^a   Rees, Daryl ^a   Andreini, Isabella ^b   Venturella, Silvana ^b   Cinelli, Serena ^b   Oberto, Germano ^b  

^a Kent Science Park   (United Kingdom)

^b Pathology Department   (Italy)

Author keywords

Biotechnology derived products; Callithrix jacchus; Marmoset; Non human primates; Nonclinical; Pharmaceuticals; Pharmacokinetics; Pharmacology; Regulatory; Toxicology

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; URIDINE DIPHOSPHATE;

AGRICULTURE; ANIMAL BEHAVIOR; ARTICLE; BIOTECHNOLOGICAL PROCEDURES; BREEDING; CALLITRICHINAE; COGNITION; CONTROLLED STUDY; DRUG DEVELOPMENT; DRUG SENSITIVITY; DRUG SYNTHESIS; EXPRESSED SEQUENCE TAG; MULTIPLE SCLEROSIS; NONHUMAN; PARKINSON DISEASE; PHARMACODYNAMICS; PRIORITY JOURNAL; REPRODUCIBILITY; SEXUAL DEVELOPMENT; SEXUAL MATURITY; TERATOLOGY; TOXICOKINETICS; TRANSGENE;

ANIMAL HUSBANDRY; ANIMALS; BODY SIZE; CALLITHRIX; FEMALE; MALE; MODELS, ANIMAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; REPRODUCIBILITY OF RESULTS; SPECIES SPECIFICITY; TOXICITY TESTS;

ANIMALIA; CALLITHRIX JACCHUS; MARMOSETS; PRIMATES;

EID: 78751569611     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2010.12.003     Document Type: Article

References (106)

1. Abbott D. Aspects of common marmoset basic biology and life history important for biomedical research. Comp. Med. 2003, 53:12.
2. Badihi I., Morris K., Buchanan-Smith H.M. The effects of increased space, complexity, and choice, together with their loss, on the behavior of a family group of Callithrix jacchus: a case study. Lab. Prim. Newslett. 2007, 46:1-5.
3. Barrett J.R. The testosterone test: phthalate inhibits leydig cell aggregation. Environ. Health Perspect. 2007, 115:A153.
4. Barton R.W., Thrall R.S., Neubauer R.H. Binding of human lymphocyte-specific monoclonal antibodies to common marmoset lymphoid cells. Cell. Immunol. 1984, 84:446-452.
5. Baskerville M. Old World monkeys. UFAW Handbook on the Care and Management of Laboratory Animals 1999, 611-635. Blackwell Science, Oxford. seventh ed. T. Poole (Ed.).
6. Boon L., Brok H.P., Bauer J., Ortiz-Buijsse A., Schellekens M.M., Ramdien-Murli S., Blezer E., van Meurs M., Ceuppens J., de Boer M., t Hart B.A., Laman J.D. Prevention of experimental autoimmune encephalomyelitis in the common marmoset (Callithrix jacchus) using a chimeric antagonist monoclonal antibody against human CD40 is associated with altered B cell responses. J. Immunol. 2001, 167:2942-2949.
7. Boretius S., Schmelting B., Watanabe T., Merkler D., Tammer R., Czeh B., Michaelis T., Frahm J., Fuchs E. Monitoring of EAE onset and progression in the common marmoset monkey by sequential high-resolution 3D MRI. NMR Biomed. 2006, 19:41-49.
8. Broadmeadow A. The common marmoset (Callithrix jacchus) in preclinical research and development of new pharmaceutical products. J. Toxicol. Sci. 2005, 30:S123.
9. Brysch W., Brysch I., Creutzfeldt O.D., Schlingensiepen R., Schlingensiepen K.H. The topology of the thalamo-cortical projections in the marmoset monkey (Callithrix jacchus). Exp. Brain Res. 1990, 81:1-17.
10. Bullock P., Pearce R., Draper A., Podval J., Bracken W., Veltman J., Thomas P., Parkinson A. Induction of liver microsomal cytochrome P450 in cynomolgus monkeys. Drug Metab. Dispos. 1995, 23:736-748.
11. Butler M.A., Guengerich F.P., Kadlubar F.F. Metabolic oxidation of the carcinogens 4-aminobiphenyl and 4,4'-methylene-bis(2-chloroaniline) by human hepatic microsomes and by purified rat hepatic cytochrome P-450 monooxygenases. Cancer Res. 1989, 49:25-31.
12. Cilia J., Piper D.C., Upton N., Hagan J.J. Clozapine enhances breakpoint in common marmosets responding on a progressive ratio schedule. Psychopharmacology (Berl.) 2001, 155:135-143.
13. Cline J.M. Assessing the mammary gland of nonhuman primates: effects of endogenous hormones and exogenous hormonal agents and growth factors. Birth Defects Res. B Dev. Reprod. Toxicol. 2007, 80:126-146.
14. Commision of the European Communities, E., 2007. Fifth Report on the Statistics on the Number of Animals used for Experimental and other Scientific Purposes in the Member States of the European Union. p. 277.
15. Cyranoski D. Marmoset model takes centre stage. Nature 2009, 459:492.
16. Datson N.A., Morsink M.C., Atanasova S., Armstrong V.W., Zischler H., Schlumbohm C., Dutilh B.E., Huynen M.A., Waegele B., Ruepp A., de Kloet E.R., Fuchs E. Development of the first marmoset-specific DNA microarray (EUMAMA): a new genetic tool for large-scale expression profiling in a non-human primate. BMC Genomics 2007, 8:190.
17. Datson N.A., Morsink M.C., Steenbergen P.J., Aubert Y., Schlumbohm C., Fuchs E., de Kloet E.R. A molecular blueprint of gene expression in hippocampal subregions CA1, CA3, and DG is conserved in the brain of the common marmoset. Hippocampus 2009, 19:739-752.
18. Davy C.W., Jackson M.R., Walker J. Reference intervals for some clinical chemical parameters in the marmoset (Callithrix jacchus): effect of age and sex. Lab. Anim. 1984, 18:135-142.
19. Dawson T.M., Dawson V.L. Neuroprotective and neurorestorative strategies for Parkinson's disease. Nat. Neurosci. 2002, 5(Suppl):1058-1061.
20. Diem R., Demmer I., Boretius S., Merkler D., Schmelting B., Williams S.K., Sattler M.B., Bahr M., Michaelis T., Frahm J., Bruck W., Fuchs E. Autoimmune optic neuritis in the common marmoset monkey: comparison of visual evoked potentials with MRI and histopathology. Invest. Ophthalmol. Vis. Sci. 2008, 49:3707-3714.
21. Dunbar S.A. Applications of Luminex xMAP technology for rapid, high-throughput multiplexed nucleic acid detection. Clin. Chim. Acta 2006, 363:71-82.
22. Dutton G.J. Glucuronidation of Drugs and Other Compounds 1980, CRC Press, Boca Raton, Florida.
23. Eason C.T., Spencer A.J., Pattison A., Howells D.D., Henry D.C., Bonner F.W. Species variation in gastric toxicity following chronic administration of ciprofibrate to rat, mouse, and marmoset. Toxicol. Appl. Pharmacol. 1988, 95:328-338.
24. Eden R.J., Costall B., Domeney A.M., Gerrard P.A., Harvey C.A., Kelly M.E., Naylor R.J., Owen D.A., Wright A. Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist. Pharmacol. Biochem. Behav. 1991, 38:147-154.
25. Edwards R.J., Murray B.P., Murray S., Schulz T., Neubert D., Gant T.W., Thorgeirsson S.S., Boobis A.R., Davies D.S. Contribution of CYP1A1 and CYP1A2 to the activation of heterocyclic amines in monkeys and human. Carcinogenesis 1994, 15:829-836.
26. Eslamboli A. Marmoset monkey models of Parkinson's disease: which model, when and why?. Brain Res. Bull. 2005, 68:140-149.
27. Eslamboli A., Romero-Ramos M., Burger C., Bjorklund T., Muzyczka N., Mandel R.J., Baker H., Ridley R.M., Kirik D. Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain 2007, 130:799-815.
28. Gaudy J.H., Sicard J.F., Lhoste F., Boitier J.F. The effects of cremophor EL in the anaesthetized dog. Can. J. Anaesth. 1987, 34:122-129.
29. Genain C.P., Hauser S.L. Creation of a model for multiple sclerosis in Callithrix jacchus marmosets. J. Mol. Med. 1997, 75:187-197.
30. Graham M.J., Wilson S.A., Winham M.A., Spencer A.J., Rees J.A., Old S.L., Bonner F.W. Lack of peroxisome proliferation in marmoset liver following treatment with ciprofibrate for 3years. Fundam. Appl. Toxicol. 1994, 22:58-64.
31. Guldin W.O., Mirring S., Grusser O.J. Connections from the neocortex to the vestibular brain stem nuclei in the common marmoset. NeuroReport 1993, 5:113-116.
32. Heger W., Klug S., Schmahl H.J., Nau H., Merker H.J., Neubert D. Embryotoxic effects of thalidomide derivatives on the non-human primate Callithrix jacchus; 3. Teratogenic potency of the EM 12 enantiomers. Arch. Toxicol. 1988, 62:205-208.
33. Heger W., Schmahl H.J., Klug S., Felies A., Nau H., Merker H.J., Neubert D. Embryotoxic effects of thalidomide derivatives in the non-human primate Callithrix jacchus. IV. Teratogenicity of micrograms/kg doses of the EM12 enantiomers. Teratog. Carcinog. Mutagen. 1994, 14:115-122.
34. Hillier S.G., Tetsuka M., Fraser H.M. Location and developmental regulation of androgen receptor in primate ovary. Hum. Reprod. 1997, 12:107-111.
35. Hoffmann-LaRoche, 2008. Product monograph: Inhibace® (cilazapril).
36. Hoffmann-LaRoche, 2009. Product monograph: Tamiflu® (oseltamivir phosphate capsule).
37. Hoffmann-LaRoche, 2009 Product monograph: Invirase® (Saquinavir mesylate).
38. Hohjoh H., Akari H., Fujiwara Y., Tamura Y., Hirai H., Wada K. Molecular cloning and characterization of the common marmoset Huntington gene. Gene 2009, 432:60-66.
39. Home-Office, 2000. Statistics of Scientific Procedures on Living Animals Great Britain.
40. Hornung J.P., Fritschy J.M., Tork I. Distribution of two morphologically distinct subsets of serotoninergic axons in the cerebral cortex of the marmoset. J. Comp. Neurol. 1990, 297:165-181.
41. 2010. (3 June 2010) - Updated Marmoset Genome Browser Available. http://ucscbrowser.genenetwork.org/goldenPath/newsarch.html.
42. 2007. Overview of 3215 sequences submitted to GenBank and dbEST (Datson et al., 2007). http://www.biomedcentral.com/content/supplementary/1471-2164-8-190-S2.xls.
43. 2010. Immunology Core Laboratory. http://www.sfbr.org/SNPRC/detail.aspx?r=60.
44. Hu R., Wang J. A rapid, multiplexed new technology xMAP liquid chip for detection and identification of pathogens. Wei Sheng Yan Jiu 2007, 36:759-762.
45. Husen B., Adamski J., Rune G.M., Einspanier A. Mechanisms of estradiol inactivation in primate endometrium. Mol. Cell. Endocrinol. 2001, 171:179-185.
46. ICH-Topic-M3(R2), 2009. Guideline on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorisation for Pharmaceuticals.
47. ICH-Topic-S7A, 2000. Safety Pharmacology Studies for Human Pharmaceuticals.
48. ICH-Topic-S7B, 2005. The Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals.
49. Kametani Y., Suzuki D., Kohu K., Satake M., Suemizu H., Sasaki E., Ito T., Tamaoki N., Mizushima T., Ozawa M., Tani K., Kito M., Arai H., Koyanagi A., Yagita H., Habu S. Development of monoclonal antibodies for analyzing immune and hematopoietic systems of common marmoset. Exp. Hematol. 2009, 37:1318-1329.
50. Kendall A.L., David F., Rayment G., Torres E.M., Annett L.E., Dunnett S.B. The influence of excitotoxic basal ganglia lesions on motor performance in the common marmoset. Brain 2000, 123(Pt 7):1442-1458.
51. Kendall A.L., Hantraye P., Palfi S. Striatal tissue transplantation in non-human primates. Prog. Brain Res. 2000, 127:381-404.
52. Kendall A.L., Rayment F.D., Torres E.M., Baker H.F., Ridley R.M., Dunnett S.B. Functional integration of striatal allografts in a primate model of Huntington's disease. Nat. Med. 1998, 4:727-729.
53. Kireta S., Zola H., Gilchrist R.B., Coates P.T. Cross-reactivity of anti-human chemokine receptor and anti-TNF family antibodies with common marmoset (Callithrix jacchus) leukocytes. Cell. Immunol. 2005, 236:115-122.
54. Kirik D., Annett L.E., Burger C., Muzyczka N., Mandel R.J., Bjorklund A. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 2003, 100:2884-2889.
55. Klug S., Felies A., Sturje H., Nogueira A.C., Neubert R., Frankus E. Embryotoxic effects of thalidomide derivatives in the non-human primate Callithrix jacchus 5 Lack of teratogenic effects of phthalimidophthalmide. Arch. Toxicol. 1994, 68:203-205.
56. Koehler S.C., Von Ahsen N., Schlumbohm C., Asif A.R., Goedtel-Armbrust U., Oellerich M., Wojnowski L., Armstrong V.W. Marmoset CYP3A21, a model for human CYP3A4: protein expression and functional characterization of the promoter. Xenobiotica 2006, 36:1210-1226.
57. Kurata Y., Takechi M., Toyota N., Tsuchitani M., Katoh M., Rusch G.M., Trochimowicz H.J., Shin-Ya S. Four-week repeated inhalation study of HCFC 225ca and HCFC 225cb in the common marmoset. Toxicol. Lett. 1997, 92:209-219.
58. Kuzel R.A., Smith J.M., Trennery P.N. Screening procedure for assessment of ototoxicity in the common marmoset. J. Pharmacol. Methods 1990, 24:9-18.
59. Luetjens C.M., Weinbauer G.F., Wistuba J. Primate spermatogenesis: new insights into comparative testicular organisation, spermatogenic efficiency and endocrine control. Biol. Rev. Camb. Philos. Soc. 2005, 80:475-488.
60. Luetjens C.M., Wesselmann R. The fate of paternal mitochondria in marmoset pre-implantation embryos. J. Med. Primatol. 2008, 37:128-140.
61. Makowska J.M., Gibson G.G., Bonner F.W. Species differences in ciprofibrate induction of hepatic cytochrome P450 4A1 and peroxisome proliferation. J. Biochem. Toxicol. 1992, 7:183-191.
62. Mansfield, K., Tardif, S., Eichler, E.E., 2004. White Paper for Complete sequencing of the common marmoset (Callithrix jacchus) genome. http://www.genome.gov/Pages/Research/Sequencing/SeqProposals/MarmosetSeq.pdf.
63. Marshall J.W., Cummings R.M., Bowes L.J., Ridley R.M., Green A.R. Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4h after occlusion. Stroke 2003, 34:2228-2233.
64. Marshall V.S., Browne M.A., Knowles L., Golos T.G., Thomson J.A. Ovarian stimulation of marmoset monkeys (Callithrix jacchus) using recombinant human follicle stimulating hormone. J. Med. Primatol. 2003, 32:57-66.
65. Marshall V.S., Kalishman J., Thomson J.A. Nonsurgical embryo transfer in the common marmoset monkey. J. Med. Primatol. 1997, 26:241-247.
66. Marshall V.S., Wilton L.J., Moore H.D. Parthenogenetic activation of marmoset (Callithrix jacchus) oocytes and the development of marmoset parthenogenones in vitro and in vivo. Biol. Reprod. 1998, 59:1491-1497.
67. Matsumoto, K., Ochiai, T., Sekita, K., Kawasaki, Y., Yasuhara, K., Nakaji, Y., Furuya, T., Kurokawa, Y., Tobe, M., 1987. Six-month toxicity study with mitomycin C in marmosets. Jpn. Soc. Toxicol., Tokyo.
68. McArthur A.G., Hegelund T., Cox R.L., Stegeman J.J., Liljenberg M., Olsson U., Sundberg P., Celander M.C. Phylogenetic analysis of the cytochrome P450 3 (CYP3) gene family. J. Mol. Evol. 2003, 57:200-211.
69. Merkler D., Schmelting B., Czeh B., Fuchs E., Stadelmann C., Bruck W. Myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in the common marmoset reflects the immunopathology of pattern II multiple sclerosis lesions. Mult. Scler. 2006, 12:369-374.
70. Millar M.R., Sharpe R.M., Weinbauer G.F., Fraser H.M., Saunders P.T. Marmoset spermatogenesis: organizational similarities to the human. Int. J. Androl. 2000, 23:266-277.
71. Committee for the Update of the Guide for the Care and Use of Laboratory Animals; National Research Council, 2010. Guide for the Care and Use of Laboratory Animals: Eighth Edition. The National Academies Press.
72. Nelson D.R., Zeldin D.C., Hoffman S.M., Maltais L.J., Wain H.M., Nebert D.W. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 2004, 14:1-18.
73. Neubert R., Foerster M., Nogueira A.C., Helge H. Cross-reactivity of antihuman monoclonal antibodies with cell surface receptors in the common marmoset. Life Sci. 1996, 58:317-324.
74. Neubert R., Hinz N., Thiel R., Neubert D. Down-regulation of adhesion receptors on cells of primate embryos as a probable mechanism of the teratogenic action of thalidomide. Life Sci. 1996, 58:295-316.
75. Neubert R., Stahlmann R., Korte M., van Loveren H., Vos J.G., Golor G., Webb J.R., Helge H., Neubert D. Effects of small doses of dioxins on the immune system of marmosets and rats. Ann. N. Y. Acad. Sci. 1993, 685:662-686.
76. Niblack G.D., Kateley J.R., Gengozian N. T-and B-lymphocyte chimerism in the marmoset. Immunology 1977, 32:257-263.
77. Oberto G., Conz A., Giachetti C., Galli C.L. Evaluation of the toxicity of indomethacin in a 4-week study, by oral route, in the marmoset (Callithrix jacchus). Fundam. Appl. Toxicol. 1990, 15:800-813.
78. OJ-L-197-(vol-50), 2007. Commission Recommendation of 18 June 2007 on guidelines for the accommodation and care of animals used for experimental and other scientific purposes (notified under document number C(2007) 2525).
79. Owen S., Thomas C., West P., Wolfensohn S., Wood M. Report on primate supply for biomedical scientific work in the UK. EUPREN UK working party. Lab. Anim. 1997, 31:289-297.
80. Pastori, F., Salerno, D., Oberto, G., Villa, S., Ricci, R., Calfapierta, F.R., 2010. Comparison and validation of Dried Blood Spot (DBS) and Solid Phase Extraction (SPE) techniques. In: XII International Congress of Toxicology. Toxicol. Lett. 196S, Barcelona, Spain.
81. Peretta G. Non-human primate models in neuroscience research. Scand. J. Lab. Anim. Sci. 2009, 36:77-85.
82. Ramaswamy S., McBride J.L., Kordower J.H. Animal models of Huntington's disease. ILAR J. 2007, 48:356-373.
83. Reddy J.K., Scarpelli D.G., Subbarao V., Lalwani N.D. Chemical carcinogens without mutagenic activity: peroxisome proliferators as a prototype. Toxicol. Pathol. 1983, 11:172-180.
84. Riecke K., Nogueira A.C., Alexi-Meskishvili V., Stahlmann R. Cross-reactivity of antibodies on thymic epithelial cells from humans and marmosets by flow-cytometry. J. Med. Primatol. 2000, 29:343-349.
85. Ross C.N., French J.A., Ortí G. Germ-line chimerism and paternal care in marmosets (Callithrix kuhlii). Proc. Natl Acad. Sci. USA 2007, 104:6278-6282.
86. Ruiz de Elvira M.C., Abbott D.H. A backpack system for long-term osmotic minipump infusions into unrestrained marmoset monkeys. Lab. Anim. 1986, 20:329-334.
87. Rumrill P.D.J. Multiple sclerosis: medical and psychosocial aspects, etiology, incidence, and prevalence. J. Voc. Rehabil. 2009, 31:75-82.
88. Sakuma T., Igarashi T., Hieda M., Ohgiya S., Isogai M., Ninomiya S., Nagata R., Nemoto N., Kamataki T. Marmoset CYP1A2: primary structure and constitutive expression in livers. Carcinogenesis 1997, 18:1985-1991.
89. Sasaki E., Suemizu H., Shimada A., Hanazawa K., Oiwa R., Kamioka M., Tomioka I., Sotomaru Y., Hirakawa R., Eto T., Shiozawa S., Maeda T., Ito M., Ito R., Kito C., Yagihashi C., Kawai K., Miyoshi H., Tanioka Y., Tamaoki N., Habu S., Okano H., Nomura T. Generation of transgenic non-human primates with germline transmission. Nature 2009, 459:523-527.
90. SCHER, 2009. The need for non human primates for biomedical research, production and testing of products and devices. European Commission. pp. 1-36.
91. Schnell C.R., Wood J.M. Measurement of blood pressure and heart rate by telemetry in conscious unrestrained marmosets. Lab. Anim. 1995, 29:258-261.
92. Sharpe R.M., Martin B., Morris K., Greig I., McKinnell C., McNeilly A.S., Walker M. Infant feeding with soy formula milk: effects on the testis and on blood testosterone levels in marmoset monkeys during the period of neonatal testicular activity. Hum. Reprod. 2002, 17:1692-1703.
93. Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 1994, 270:414-423.
94. Smith D., Trennery P., Farningham D., Klapwijk J. The selection of marmoset monkeys (Callithrix jacchus) in pharmaceutical toxicology. Lab. Anim. 2001, 35:117-130.
95. Soars M.G., Riley R.J., Burchell B. Evaluation of the marmoset as a model species for drug glucuronidation. Xenobiotica 2001, 31:849-860.
96. Spencer A.J., Barbolt T.A., Henry D.C., Eason C.T., Sauerschell R.J., Bonner F.W. Gastric morphological changes including carcinoid tumors in animals treated with a potent hypolipidemic agent, ciprofibrate. Toxicol. Pathol. 1989, 17:7-15.
97. Summers P.M., Shephard A.M., Taylor C.T., Hearn J.P. The effects of cryopreservation and transfer on embryonic development in the common marmoset monkey, Callithrix jacchus. J. Reprod. Fertil. 1987, 79:241-250.
98. t Hart B.A., Brok H.P., Remarque E., Benson J., Treacy G., Amor S., Hintzen R.Q., Laman J.D., Bauer J., Blezer E.L. Suppression of ongoing disease in a nonhuman primate model of multiple sclerosis by a human-anti-human IL-12p40 antibody. J. Immunol. 2005, 175:4761-4768.
99. t Hart B.A., Massacesi L. Clinical, pathological, and immunologic aspects of the multiple sclerosis model in common marmosets (Callithrix jacchus). J. Neuropathol. Exp. Neurol. 2009, 68:341-355.
100. t Hart B.A., van Meurs M., Brok H.P., Massacesi L., Bauer J., Boon L., Bontrop R.E., Laman J.D. A new primate model for multiple sclerosis in the common marmoset. Immunol. Today 2000, 21:290-297.
101. Tan K.A., Walker M., Morris K., Greig I., Mason J.I., Sharpe R.M. Infant feeding with soy formula milk: effects on puberty progression, reproductive function and testicular cell numbers in marmoset monkeys in adulthood. Hum. Reprod. 2006, 21:896-904.
102. Tucker M.J. A survey of the pathology of marmosets (Callithrix jacchus) under experiment. Lab. Anim. 1984, 18:351-358.
103. Wadsworth P.F., Budgett D.A., Forster M.L. Organ weight data in juvenile and adult marmosets (Callithrix jacchus). Lab. Anim. 1981, 15:385-388.
104. Weatherall D. The Use of Non-Human Primates in Research 2006, Academy of Medical Sciences, London, p. 147.
105. Williams E.T., Rodin A.S., Strobel H.W. Defining relationships between the known members of the cytochrome P450 3A subfamily, including five putative chimpanzee members. Mol. Phylogen. Evol. 2004, 33:300-308.
106. Zuhlke U., Weinbauer G. The common marmoset (Callithrix jacchus) as a model in toxicology. Toxicol. Pathol. 2003, 31(Suppl):123-127.